日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

新诊断和复发/难治性多发性骨髓瘤中细胞遗传学异常与高危疾病的共存

Kaiser, Martin F; Sonneveld, Pieter; Cairns, David A; Raab, Marc S; San-Miguel Izquierdo, Jesús; Zhang, Rick; Acosta, Jorge; Larocca, Alessandra; Popat, Rakesh; Li, Cong; Baertsch, Marc-A; Brown, Sarah R; Lahuerta Palacios, JuanJose; Gandhi, Anita K; Macé, Sandrine; Musto, Pellegrino; Yong, Kwee; Mai, Elias K; Dubin, Franck; Blade, Joan; Capra, Andrea; Cook, Gordon; Bertsch, Uta; Mateos, María-Victoria; Boccadoro, Mario; Jackson, Graham H; Gutiérrez, Norma C; Gay, Francesca; Weinhold, Niels

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling

通过转录组和基因谱分析挑战功能性高危骨髓瘤的概念

Beer, Sina A; Cairns, David A; Pawlyn, Charlotte; Holroyd, Amy; Ferris, Elsa; Cook, Gordon; Drayson, Mark; Boyd, Kevin; Proszek, Paula; Davies, Faith E; de Tute, Ruth; Jenner, Matthew; Morgan, Gareth J; Owen, Roger; Hubank, Michael; Houlston, Richard; Jackson, Graham; Kaiser, Martin F

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform

基于机器学习的多发性骨髓瘤风险分层策略:来自 EMN-HARMONY 联盟平台的启示

Mosquera Orgueira, Adrian; Gonzalez Perez, Marta Sonia; D'Agostino, Mattia; Cairns, David A; Larocca, Alessandra; Palacios, Juan José Lahuerta; Wester, Ruth; Bertsch, Uta; Waage, Anders; Zamagni, Elena; Pérez Míguez, Carlos; Rojas Martínez, Javier Alberto; Mai, Elias K; Crucitti, Davide; Salwender, Hans; Dall'Olio, Daniele; Castellani, Gastone; Piñeiro Fiel, Manuel; Bringhen, Sara; Zweegman, Sonja; Cavo, Michele; Iqbal, Sofía; Hernandez Rivas, Jesus Maria; Bruno, Benedetto; Cook, Gordon; Kaiser, Martin F; Goldschmidt, Hartmut; Van De Donk, Niels W C J; Jackson, Graham; San-Miguel, Jesús F; Boccadoro, Mario; Mateos, Maria-Victoria; Sonneveld, Pieter

Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis

接受全身抗癌治疗的成年患者的虚弱状况与预后:系统评价和荟萃分析

Pearce, Jessica; Martin, Sally; Heritage, Sophie; Khoury, Emma G; Kucharczak, Joanna; Nuamek, Thitikorn; Cairns, David A; Velikova, Galina; Richards, Suzanne H; Clegg, Andrew; Gilbert, Alexandra

How should overall survival be analysed in randomised clinical trials in cancer if participants receive subsequent treatment lines? A stakeholder consultation

如果癌症随机临床试验的参与者接受了后续治疗,应如何分析总生存期?利益相关者咨询

Royle, Kara-Louise; Wheatstone, Peter; Meads, David; Visser-Rogers, Jennifer K; White, Ian R; Cairns, David A

Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm

无进展生存期作为多发性骨髓瘤临床试验的替代终点:一个不断发展的范式

Pawlyn, Charlotte; Schjesvold, Fredrik H; Cairns, David A; Wei, L J; Davies, Faith; Nadeem, Omar; Abdulhaq, Haifaa; Mateos, Maria-Victoria; Laubach, Jacob; Weisel, Katja; Ludwig, Heinz; Rajkumar, S Vincent; Sonneveld, Pieter; Jackson, Graham; Morgan, Gareth; Richardson, Paul G

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

通过扩展基因谱分析优化来那度胺维持治疗的价值:一项对 556 例骨髓瘤 XI 试验患者的分析

Panopoulou, Aikaterini; Cairns, David A; Holroyd, Amy; Nichols, Isabel; Cray, Nikita; Pawlyn, Charlotte; Cook, Gordon; Drayson, Mark; Boyd, Kevin; Davies, Faith E; Jenner, Matthew; Morgan, Gareth J; Owen, Roger; Houlston, Richard; Jackson, Graham; Kaiser, Martin F

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

对新诊断的、适合和不适合移植的多发性骨髓瘤患者进行来那度胺维持治疗;对接受 XI 试验治疗的 4358 例患者进行第二原发性恶性肿瘤的分析

Jones, John R; Cairns, David A; Menzies, Tom; Pawlyn, Charlotte; Davies, Faith E; Sigsworth, Rachel; Brioli, Annamaria; Jenner, Matthew W; Kaiser, Martin F; Olivier, Catherine; Reed, Molly; Drayson, Mark T; Owen, Roger G; Boyd, Kevin D; Cook, Gordon; Morgan, Gareth J; Jackson, Graham H

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

NET-02:一项随机、非对照的II期临床试验,旨在评估nal-IRI/5-FU或多西他赛作为二线疗法治疗进展性低分化肺外神经内分泌癌患者的疗效。

McNamara, Mairéad G; Swain, Jayne; Craig, Zoe; Sharma, Rohini; Faluyi, Olusola; Wadsley, Jonathan; Morgan, Carys; Wall, Lucy R; Chau, Ian; Reed, Nick; Sarker, Debashis; Margetts, Jane; Krell, Daniel; Cave, Judith; Sothi, Sharmila; Anthoney, Alan; Bell, Christopher; Patel, Alkesh; Oughton, Jamie B; Cairns, David A; Mansoor, Wasat; Lamarca, Angela; Hubner, Richard A; Valle, Juan W

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

在来那度胺维持治疗的基础上加用伏立诺他治疗所有年龄段新诊断的多发性骨髓瘤患者:来自“Myeloma XI”多中心、开放标签、随机、III期试验的结果

Jenner, Matthew W; Pawlyn, Charlotte; Davies, Faith E; Menzies, Tom; Hockaday, Anna; Olivier, Catherine; Jones, John R; Karunanithi, Kamaraj; Lindsay, Jindriska; Kishore, Bhuvan; Cook, Gordon; Drayson, Mark T; Kaiser, Martin F; Owen, Roger G; Gregory, Walter; Cairns, David A; Morgan, Gareth J; Jackson, Graham H